Drug Trial Radar · NCT05363722
Clinical Study on Efficacy and Safety of IBI310, Bevacizumab Combined With Sintilimab in Advanced HCC
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Mar 6, 2025
Primary completion
Jan 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Shanghai Zhongshan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, multicenter phase Ib study to evaluate the effectiveness and safety of IBI310, bevacizumab combined with sintilimab in patients with locally advanced or metastatic HCC who have not previously received systemic therapy, are unsuitable for radical surgical resection or local treatment, or have progressive disease after surgical resection or local treatment.
Conditions
- Hepatocellular Carcinoma
Interventions
IBI310(1mg/kg)Drug
IBI310 1mg/kg IV d1 Q6W
sintilimabDrug
sintilimab 200 mg IV d1 Q3W
bevacizumabDrug
bevacizumab 15 mg/kg IV d1,Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment Emergent Adverse Event, TEAETime frame: Any emergent adverse event from first dose through study completion, up to 2 years.
- Severe Adverse Event, SAETime frame: Any severe adverse event from first dose through study completion, up to 2 years.
- Objective response rate (ORR)Time frame: The proportion of patients with complete response or partial response, through study completion, up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital, Fudan University
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.